Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

0HD2.L

Get informed when a big investor buys or sells

+ Follow
Market Cap$31.13B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Alnylam Pharmaceuticals, Inc.Alnylam Pharmaceuticals, Inc.38.1-60%6.40.9

Share Statistics

Market cap$31.13 Billion
Enterprise Value$30.70 Billion
Dividend Yield$- (-)
Earnings per Share$2.39
Beta0.27
Outstanding Shares135,945,454

Return

Return on Equity59.67%ROE
Return on Assets14.54%
Return on Invested Capital19.74%

Valuation & Multiples

P/E Ratio38.14P/E Ratio
PEG-10.95PEG
Price to Sales6.37Price to Sales
Price to Book Ratio24.75Price to Book Ratio
Enterprise Value to Revenue6.39
Enterprise Value to EBIT38.44
Enterprise Value to Net Income37
Total Debt to Enterprise0.04
Debt to Equity0.94Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
July 30, 2026
EPS Estimate
$1.63
Average shareholder expectation
Revenue Estimate
$1.32 B
Average shareholder expectation

Next Earnings Call

Expected Date
October 29, 2026
EPS Estimate
$1.75
Average shareholder expectation
Revenue Estimate
$1.43 B
Average shareholder expectation

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

ESG Score

No data

About Alnylam Pharmaceuticals Inc

2,500 employees
CEO: John Maraganore

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the exploration, advancement, and marketing of innovative therapies rooted in RNA interference (RNAi) technology. The company's research pipeline for RNAi treatmen...